公开(公告)号：US20220257862A1

公开(公告)日：2022-08-18

申请号：US17534173

申请日：2021-11-23

Applicant: AMGEN INC.

Inventor： Adam B. McCullough ,  Ferry Tamtoro ,  Huaying Yang ,  Mark Ka Lai Lee ,  Desheng Yin ,  Scott R. Gibson ,  Donald Busby ,  Peter V. Shultz ,  Keith P. Kogler ,  Basel Hasan Taha ,  Jimmie L. Ward ,  Christopher R. Folk ,  Steven William Badelt

IPC: A61M5/20 ,  A61M5/315 ,  A61M5/32 ,  A61M5/142 ,  A61M5/50 ,  G16H20/17 ,  G16H40/63 ,  G16H40/00 ,  G16H40/67 ,  G06Q50/22 ,  G06Q50/00 ,  A61M5/158 ,  A61M5/24

Abstract: A drug delivery system is disclosed that includes a drug delivery device having a reservoir, a delivery cannula having a proximal end in fluid communication with the reservoir and a distal end to be received within a patient, and one or more controllable elements. The drug delivery system may further include one or more sensors coupled to the drug delivery device, and a controller coupled to the one or more sensors and the one or more controllable elements. The controller may be configured to use the one or more sensors to determine a condition or an operational state of the drug delivery device. Furthermore, the controller may be configured to control the controllable element based on the condition or the operational state of the drug delivery device and/or identity information stored in a memory onboard the device. A method for use with a drug delivery device is also disclosed.

公开(公告)号：US20220218900A1

公开(公告)日：2022-07-14

申请号：US17688578

申请日：2022-03-07

Applicant: AMGEN INC.

Inventor： Scott R. Gibson ,  Sheldon B, Moberg ,  Basel Hasan Taha ,  Margaux Frances Boyaval ,  Mark A. Destefano ,  John C. Love ,  Ian B. Hanson ,  Paul F. Bente, IV ,  Matthew J. Clemente ,  Rajan Ramaswamy ,  Daniel S. Codd ,  Scott Beaver ,  Kevin L. Bokelman ,  Sean M. O'connor ,  Robert Decker ,  Gautam N. Shetty ,  Ryan M. Agard ,  Nicholas J. Ciccarelli ,  Daniel Davenport

IPC: A61M5/142 ,  A61M5/145 ,  A61M5/315

Abstract: Disclosed herein is a wearable drug delivery device including a container filled at least partially with a drug including at least one of a PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) specific antibody, a granulocyte colony-stimulating factor (G-CSF), a sclerostin antibody, or a calcitonin gene-related peptide (CGRP) antibody. The wearable drug delivery device may include a needle and an insertion mechanism configured to insert the needle into a patient. A fluid pathway connector may define a sterile fluid flowpath between the container and the insertion mechanism. Optionally, a cannula initially disposed about the needle may be included. The cannula may be retained in the patient at an injection site created by the needle after the needle is withdrawn from the patient. Methods of assembly and operation are also provided.

公开(公告)号：US20220031953A1

公开(公告)日：2022-02-03

申请号：US17277555

申请日：2019-10-22

Applicant: AMGEN INC.

Inventor： Ali Nekouzadeh ,  Carl Conrath ,  Basel Hasan Taha

IPC: A61M5/315 ,  A61M5/20

Abstract: Methods, devices, and components are provided to reduce tissue resistive pressure during a subcutaneous drug delivery operation by increasing the size of the injection cavity by partially retracting the drug delivery member after inserting the drug delivery member to a subcutaneous position. The drug delivery devices described herein include a resilient member that interacts between stationary and moveable components of the drug delivery device. The drug delivery device include drives to move the stationary and moveable components relative to one another to insert a drug delivery member to a subcutaneous depth within a patient and to dispense a drug to the injection cavity in the patient. The resilient member is deformed during the operations or is pre-deformed and the stored energy of the resilient member in the deformed state then acts on the stationary and moveable components to partially retract the drug delivery member to relieve pressure in the injection region.

公开(公告)号：US20200316291A1

公开(公告)日：2020-10-08

申请号：US16089685

申请日：2017-04-07

Applicant: AMGEN INC.

Inventor： Scott Robert Gibson ,  Sheldon B. Moberg ,  Basel Hasan Taha ,  Margaux Frances Boyaval ,  Mark A. Destefano ,  Lawton Laurence ,  John C. Love ,  Ian B. Hanson ,  Paul F. Bente, IV ,  Matthew J. Clemente ,  Antonio Ubach ,  Rajan Ramaswamy ,  Daniel S. Codd ,  Scott Beaver ,  Kevin L. Bokelman ,  Ian P. Dardani ,  Sean M. O'connor ,  Danielle Feldman

IPC: A61M5/145 ,  A61M5/158 ,  A61M5/142

Abstract: Disclosed herein is a wearable drug delivery device including a container filled at least partially with a drug including at least one of a PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) specific antibody, a granulocyte colony-stimulating factor CSF), a sclerostin antibody, or a calcitonin gene-related peptide (CGRP) antibody. The wearable drug delivery device includes a needle and an insertion mechanism configured to insert the needle into a patient. A fluid pathway connector defines a sterile fluid flowpath between the container and the insertion mechanism. A cannula initially disposed about the needle is included.

公开(公告)号：US20170124285A1

公开(公告)日：2017-05-04

申请号：US15315922

申请日：2015-06-03

Applicant: AMGEN INC.

Inventor： Adam B. McCullough ,  Ferry Tamtoro ,  Huaying Yang ,  Mark Ka Lai Lee ,  Desheng Yin ,  Scott R. Gibson ,  Donald Busby ,  Peter V. Shultz ,  Keith P. Kogler ,  Basel Hasan Taha ,  Jimmie L. Ward ,  Steven William Badelt

IPC: G06F19/00 ,  A61M5/315 ,  A61M5/32 ,  A61M5/20

CPC classification number: A61M5/20 ,  A61M5/14244 ,  A61M5/14248 ,  A61M5/158 ,  A61M5/24 ,  A61M5/31501 ,  A61M5/31568 ,  A61M5/3202 ,  A61M5/3243 ,  A61M5/3257 ,  A61M5/326 ,  A61M5/5086 ,  A61M2005/3267 ,  A61M2205/3331 ,  A61M2205/3368 ,  A61M2205/3553 ,  A61M2205/3576 ,  A61M2205/50 ,  A61M2205/502 ,  A61M2205/52 ,  A61M2205/581 ,  A61M2205/6009 ,  G06F19/325 ,  G06F19/3418 ,  G06F19/3468 ,  G06Q50/01 ,  G06Q50/22

Abstract: Devices and methods are disclosed for assisting a user of a drug delivery device with an application executing on a mobile computing device. The mobile computing device may receive information from the drug delivery device related to its condition and/or operation and subsequently select an informational and/or instructional prompt to be displayed to the user based on the received information. The mobile computing device may also generate a display in the application including the selected informational prompt and/or the instructional prompt. Accordingly, the user of the drug delivery device can be guided through the drug delivery process in real time, thereby reducing the likelihood of improper or incomplete use of the drug delivery device.